The final, formatted version of the article will be published soon.
CLINICAL TRIAL article
Front. Neurosci.
Sec. Neuropharmacology
Volume 18 - 2024 |
doi: 10.3389/fnins.2024.1451060
Observations on the efficacy of edaravone dexborneol in preventing post-stroke depression and its inflammatory mechanism: A prospective, randomized, control Trial
Provisionally accepted- 1 Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China
- 2 Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Cangzhou, Hebei Province, China
Objective This study aimed to observe the effect of edaravone dexborneol (EDB) on the incidence of early post-stroke depression (PSD) and explore its inflammatory mechanisms. Methods A prospective, randomized controlled study was conducted from January 2022 to June 2023, involving patients with acute ischemic stroke (AIS) at the Neurology Department of the Third Affiliated Hospital of Beijing University of Traditional Chinese Medicine. The control group received routine treatment, while the experimental group received routine combined EDB treatment. The main outcome measures included PSD incidence, Patient Health Questionnaire (PHQ-9) and Hamilton Depression Scale (HAMD) scores on days 14 and 30, and inflammatory factor levels on day 14. Results A total of 93 patients were included in the study, 51 in the experimental group and 42 in the control group. On day 14, the PSD incidence was 13.7% in the experimental group, lower than 31.0% in the control group (95%CI 0.127 to 0.996; P = 0.044). Compared to the control group, the experimental group showed significantly lower concentrations of pro-inflammatory cytokines IL-1β (95%CI 3.353 to 5.184), IL-6 (95%CI 2.694 to 3.426), TNF-α (95%CI 4.985 to 12.196), IFN-γ (95%CI 0.163 to 0.451), MCP-1 (95%CI 0.335 to 0.787), IL-17A (95%CI 0.543 to 1.024), and IL-23p19 (95%CI 1.677 to 1.959)(all P < 0.001), and higher levels of anti-inflammatory cytokines IL-4 (95%CI -1.087 to -0.941), IL-10 (95%CI -6.125 to -1.662), and IL-13 (95%CI -6.078 to -2.953)(all P ≤ 0.001). On day 30, the PSD incidence in the experimental group was 15.7%, lower than 40.5% in the control group (95%CI 0.103 to 0.725; P = 0.007). Compared with the control group, the experimental group had lower PHQ-9 scores on day 14 (95%CI 0.034 to 1.577; P = 0.041) and day 30 (95%CI 0.018 to 1.573; P = 0.045), and also had lower HAMD scores on day 14 (95% CI 0.281 to 2.856; P = 0.018) and day 30 ( 95% CI 0.647 to 3.482; P = 0.005). Conclusion EDB could reduce the incidence of early PSD, reduce pro-inflammatory cytokine levels, and elevate anti-inflammatory cytokine levels, which was possibly related to the anti-inflammatory mechanism of EDB.
Keywords: edaravone dexborneol, post-stroke depression, Inflammation, cytokine, Incidence rate
Received: 18 Jun 2024; Accepted: 26 Aug 2024.
Copyright: © 2024 Xu, Li, Xu, Yuan, Zheng and Sun. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lan Li, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine, Cangzhou, Hebei Province, China
Bu Xu, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China
Shanfang Yuan, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China
Qin Zheng, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China
Wenjun Sun, Beijing University of Chinese Medicine Third Affiliated Hospital, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.